Lost or damaged prescriptions cost Canadians more than $35 million in productivity, extra travel and time spent filling prescriptions and the potential for adverse health events due to medications that aren’t taken at all, according to a new study by Canada Health Infoway. The study found 40 per cent of Canadians who lost or damaged prescriptions […]
The vast majority (87 per cent) of physicians said the knowledge that a patient has private drug coverage affects their prescribing behaviour, according to a survey by Merck Canada Inc. More specifically, the survey found 26 per cent of general practitioners and 28 per cent of specialists believe this knowledge widens the treatment options available to the patient. Other effects […]
Between 2012 and 2016, Canada’s total private drug claims market increased by a 4.7 per cent compound annual growth rate, according to new research by Innovative Medicines Canada. The analysis, which is based on IQVIA Inc.’s Canadian private drug plan claims database, aims to highlight the key drivers of private drug plan cost growth for the period. “Often the […]
There were almost 4,000 opioid-related deaths in Canada in 2017, according to Health Canada statistics released in June. Meanwhile, in the United States, a new survey by the National Business Group on Health found 60 per cent of large employers had experienced at least one issue stemming from prescription opioid misuse or abuse in the workplace. Forty […]
With an eye toward dismantling the barriers many Canadians face in accessing prescription drugs, the federal government is launching an online consultation process on national pharmacare. The government’s advisory council, introduced in the 2018 budget, is accepting views through an online questionnaire and written submissions. As well, the online platform will include a discussion forum. “Hearing directly from Canadians […]
Orphan drugs represent a significant and growing share of new pharmaceutical entrants in Canada, according to a new report from the Patented Medicine Prices Review Board. At 54 per cent of new pharmaceuticals entering the market in 2015 and 42 per cent in 2016, orphan drugs have seen a significant rise from an average of 33 […]
With governments having announced a number of changes related to pharmaceutical policy, plan sponsors are facing a shifting environment for their drug plans. “There are a lot of things happening today in the world of pharmaceuticals, drug plans, benefit plans, pricing, reimbursement and access to drugs,” said Wayne Critchley, senior associate for the health and […]
With a number of government reforms and new policies in the works, plan sponsors may well wonder about the potential impact on private drug plans. With that in mind, Suzanne Lepage, a private health plan strategist, led a panel discussion on new government policies and programs in the works at the Face to Face Drug […]
Counterfeit pharmaceutical drugs are a rising risk to Canadians as they’re appearing in brick-and-mortar pharmacies, rather than just on the street or online, according to a new report by public policy think tank the Fraser Institute. It’s also a growing issue internationally and one that’s attracting the attention of policy-makers. But what does it mean for group benefits plans? Counterfeit […]
Canadians continue to pay more than most other Organisation for Economic Co-operation and Development countries for generic drugs, despite provincial and territorial policies that have greatly reduced prices in recent years, according to a new report by the Patented Medicine Prices Review Board. The Generics360 report found Canadians spent $165 per capita on generic drugs […]